Seeking Alpha Portfolio App for iPad
Dividends & Income
View as an RSS Feed
View TraderBill's Comments
Celgene Sets The Stage For Patient Investors
I agree with the observations in this article but one additional point needs to be made. The recent slide in Celgene was exacerbated by more public release that Revlimid can increase the risk of secondary cancers.
I have Multiple Myeloma and Revlimid is one of the three treatments I take. I have known this was a possible risk for at least 5 months. I go to Mayo, Jacksonville, for my quarterly tests including a PET/CT Scan and then meet with my Oncologist late in the afternoon. Of course my health is concern #1, but I will get the latest updates on the feelings toward Revlimid and Pomalidomide. As bid and as important as Revlimid is to Celgene, I believe Pomalidomide will prove more effective with less side effects.
I am long both Celgene & Onyx in the Biopharmaceutical space.
May 9 01:00 AM
Link to Comment
The Opinion Leaders
Xignite quote data
© 2013 Seeking Alpha